Michael Root, MD, PhD

Contact Dr. Root

233 S. 10th Street
Room 802
Philadelphia, PA 19107

(215) 503-4564
(215) 923-2117 fax

Most Recent Peer-reviewed Publications

  1. Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity
  2. Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors
  3. Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
  4. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus
  5. Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources
  6. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation
  7. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors
  8. Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5
  9. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance
  10. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding
  11. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil
  12. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection
  13. Neutralization of Botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain
  14. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins
  15. A human monoclonal antibody that binds serotype A botulinum neurotoxin
  16. C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells
  17. Kinetic dependence to HIV-1 entry inhibition
  18. HIV-1 gp41 as a target for viral entry inhibition
  19. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein
  20. Protein design of an HIV-1 entry inhibitor